PMC:7502678 / 10682-11419 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T49","span":{"begin":86,"end":89},"obj":"Disease"},{"id":"T50","span":{"begin":121,"end":129},"obj":"Disease"}],"attributes":[{"id":"A49","pred":"mondo_id","subj":"T49","obj":"http://purl.obolibrary.org/obo/MONDO_0020333"},{"id":"A50","pred":"mondo_id","subj":"T50","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Almost no respondents had seen unusual interactions between anti-seizure medications (ASM) and medications used to treat COVID-19. Medications shortages were noted by approximately 44% of respondents (Figure 5). In write-in comments, the most frequently noted shortages were of extended release levetiracetam and midazolam, and other shortages of several IV benzodiazepines were noted by some respondents. However, it appears some of these shortages existed from prior to the pandemic. By and large, there appeared to be no consistent pattern of shortages of conventional ASMs directly attributable to the pandemic. The majority of shortage reports originated from patients; IV anesthetic shortages were reported by inpatient pharmacies."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T10","span":{"begin":295,"end":308},"obj":"Chemical"},{"id":"T11","span":{"begin":313,"end":322},"obj":"Chemical"},{"id":"T12","span":{"begin":355,"end":357},"obj":"Chemical"},{"id":"T13","span":{"begin":358,"end":373},"obj":"Chemical"},{"id":"T14","span":{"begin":675,"end":677},"obj":"Chemical"}],"attributes":[{"id":"A10","pred":"chebi_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/CHEBI_6437"},{"id":"A11","pred":"chebi_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/CHEBI_6931"},{"id":"A12","pred":"chebi_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/CHEBI_74327"},{"id":"A13","pred":"chebi_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/CHEBI_22720"},{"id":"A14","pred":"chebi_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/CHEBI_74327"}],"text":"Almost no respondents had seen unusual interactions between anti-seizure medications (ASM) and medications used to treat COVID-19. Medications shortages were noted by approximately 44% of respondents (Figure 5). In write-in comments, the most frequently noted shortages were of extended release levetiracetam and midazolam, and other shortages of several IV benzodiazepines were noted by some respondents. However, it appears some of these shortages existed from prior to the pandemic. By and large, there appeared to be no consistent pattern of shortages of conventional ASMs directly attributable to the pandemic. The majority of shortage reports originated from patients; IV anesthetic shortages were reported by inpatient pharmacies."}

{"project":"LitCovid-PubTator","denotations":[{"id":"174","span":{"begin":665,"end":673},"obj":"Species"},{"id":"175","span":{"begin":295,"end":308},"obj":"Chemical"},{"id":"176","span":{"begin":313,"end":322},"obj":"Chemical"},{"id":"177","span":{"begin":358,"end":373},"obj":"Chemical"},{"id":"178","span":{"begin":65,"end":72},"obj":"Disease"},{"id":"179","span":{"begin":121,"end":129},"obj":"Disease"}],"attributes":[{"id":"A174","pred":"tao:has_database_id","subj":"174","obj":"Tax:9606"},{"id":"A175","pred":"tao:has_database_id","subj":"175","obj":"MESH:D000077287"},{"id":"A176","pred":"tao:has_database_id","subj":"176","obj":"MESH:D008874"},{"id":"A177","pred":"tao:has_database_id","subj":"177","obj":"MESH:D001569"},{"id":"A178","pred":"tao:has_database_id","subj":"178","obj":"MESH:D012640"},{"id":"A179","pred":"tao:has_database_id","subj":"179","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Almost no respondents had seen unusual interactions between anti-seizure medications (ASM) and medications used to treat COVID-19. Medications shortages were noted by approximately 44% of respondents (Figure 5). In write-in comments, the most frequently noted shortages were of extended release levetiracetam and midazolam, and other shortages of several IV benzodiazepines were noted by some respondents. However, it appears some of these shortages existed from prior to the pandemic. By and large, there appeared to be no consistent pattern of shortages of conventional ASMs directly attributable to the pandemic. The majority of shortage reports originated from patients; IV anesthetic shortages were reported by inpatient pharmacies."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T35","span":{"begin":65,"end":72},"obj":"Phenotype"}],"attributes":[{"id":"A35","pred":"hp_id","subj":"T35","obj":"http://purl.obolibrary.org/obo/HP_0001250"}],"text":"Almost no respondents had seen unusual interactions between anti-seizure medications (ASM) and medications used to treat COVID-19. Medications shortages were noted by approximately 44% of respondents (Figure 5). In write-in comments, the most frequently noted shortages were of extended release levetiracetam and midazolam, and other shortages of several IV benzodiazepines were noted by some respondents. However, it appears some of these shortages existed from prior to the pandemic. By and large, there appeared to be no consistent pattern of shortages of conventional ASMs directly attributable to the pandemic. The majority of shortage reports originated from patients; IV anesthetic shortages were reported by inpatient pharmacies."}

{"project":"LitCovid-sentences","denotations":[{"id":"T95","span":{"begin":0,"end":130},"obj":"Sentence"},{"id":"T96","span":{"begin":131,"end":211},"obj":"Sentence"},{"id":"T97","span":{"begin":212,"end":405},"obj":"Sentence"},{"id":"T98","span":{"begin":406,"end":485},"obj":"Sentence"},{"id":"T99","span":{"begin":486,"end":615},"obj":"Sentence"},{"id":"T100","span":{"begin":616,"end":737},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Almost no respondents had seen unusual interactions between anti-seizure medications (ASM) and medications used to treat COVID-19. Medications shortages were noted by approximately 44% of respondents (Figure 5). In write-in comments, the most frequently noted shortages were of extended release levetiracetam and midazolam, and other shortages of several IV benzodiazepines were noted by some respondents. However, it appears some of these shortages existed from prior to the pandemic. By and large, there appeared to be no consistent pattern of shortages of conventional ASMs directly attributable to the pandemic. The majority of shortage reports originated from patients; IV anesthetic shortages were reported by inpatient pharmacies."}